

**Lifetime Probability of Developing and Dying from Cancer, 2017-2019**

|                                | MALES      |         |       |         | FEMALES    |         |       |         |
|--------------------------------|------------|---------|-------|---------|------------|---------|-------|---------|
|                                | Developing |         | Dying |         | Developing |         | Dying |         |
|                                | %          | 1 in... | %     | 1 in... | %          | 1 in... | %     | 1 in... |
| <b>All Sites*</b>              | 40.9       | 2       | 20.2  | 5       | 39.1       | 3       | 17.7  | 6       |
| Brain & ONS                    | 0.7        | 147     | 0.5   | 189     | 0.5        | 188     | 0.4   | 241     |
| Breast                         | 0.1        | 727     | <0.1  | 3,312   | 12.9       | 8       | 2.5   | 39      |
| Colorectal                     | 4.3        | 23      | 1.7   | 58      | 3.9        | 26      | 1.6   | 63      |
| Esophagus                      | 0.8        | 128     | 0.7   | 138     | 0.2        | 439     | 0.2   | 524     |
| Hodgkin lymphoma               | 0.2        | 435     | <0.1  | 2,899   | 0.2        | 532     | <0.1  | 3,819   |
| Kidney & renal pelvis          | 2.3        | 44      | 0.6   | 177     | 1.3        | 75      | 0.3   | 316     |
| Larynx                         | 0.5        | 200     | 0.2   | 570     | 0.1        | 852     | <0.1  | 2,346   |
| Leukemia                       | 1.8        | 55      | 0.9   | 108     | 1.3        | 78      | 0.7   | 152     |
| Liver & intrahepatic bile duct | 1.5        | 66      | 1.0   | 96      | 0.7        | 146     | 0.6   | 181     |
| Lung & bronchus                | 6.2        | 16      | 4.7   | 21      | 5.8        | 17      | 4.0   | 25      |
| Melanoma of skin†              | 3.5        | 28      | 0.4   | 240     | 2.4        | 41      | 0.2   | 465     |
| Myeloma                        | 0.9        | 106     | 0.5   | 219     | 0.7        | 134     | 0.4   | 275     |
| Non-Hodgkin lymphoma           | 2.3        | 43      | 0.8   | 128     | 1.9        | 53      | 0.6   | 167     |
| Oral cavity & pharynx          | 1.7        | 60      | 0.4   | 240     | 0.7        | 141     | 0.2   | 537     |
| Ovary                          | --         | --      | --    | --      | 1.1        | 88      | 0.8   | 123     |
| Pancreas                       | 1.7        | 59      | 1.4   | 71      | 1.6        | 61      | 1.4   | 73      |
| Prostate                       | 12.6       | 8       | 2.4   | 41      | --         | --      | --    | --      |
| Stomach                        | 1.0        | 102     | 0.4   | 246     | 0.6        | 157     | 0.3   | 359     |
| Testis                         | 0.4        | 246     | <0.1  | 4,966   | --         | --      | --    | --      |
| Thyroid                        | 0.6        | 155     | 0.1   | 1,706   | 1.7        | 59      | 0.1   | 1,440   |
| Urinary bladder‡               | 3.6        | 28      | 0.9   | 111     | 1.1        | 91      | 0.3   | 294     |
| Uterine cervix                 | --         | --      | --    | --      | 0.7        | 153     | 0.2   | 466     |
| Uterine corpus                 | --         | --      | --    | --      | 3.1        | 33      | 0.7   | 152     |

\*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic Whites.

‡Includes invasive and in situ cancer cases.

**Source:** Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.8.0, National Cancer Institute, 2022.